ONCOIMMUNITY
12.3.2019 18:24:09 CET | Business Wire | Press release
Flow Pharma Inc ., a San Francisco Bay Area biotechnology company focused on developing personalized cancer vaccines, today announced a collaboration with Norwegian bioinformatics company OncoImmunity AS .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190312005768/en/
Under the agreement OncoImmunity will license the Immuneoprofiler™ software to Flow Pharma to support the clinical development and commercialisation of products based on the FlowVax platform . The Immuneoprofiler™ has recently received the CE-IVD mark certification as a medical device, and fills some of the key gaps in neoantigen prediction. The FlowVax vaccine platform developed by Flow Pharma , is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack. OncoImmunity will develop a customised machine-learning layer, using clinical data generated by Flow Pharma , that will work-in-sync with the Immuneoprofiler™ software to make predictions tailored to the FlowVax platform.
“This exciting partnership and licensing deal represents a fantastic opportunity for OncoImmunity to apply its Immuneoprofiler™ prediction software to the FlowVax technology in a clinical setting. It also affords OncoImmunity the opportunity to leverage its in-depth knowledge of immune-informatics and expertise in machine learning to develop a customised solution for the FlowVax platform that will support Flow Pharma’s needs now and in the years ahead” said Richard Stratford ., Chief Executive Officer at OncoImmunity.
“We believe that OncoImmunity’s Immuneoprofiler™ software represents the best-in-class solution for predicting clinically relevant bona fide neoantigens. Flow Pharma’s bioinformatics team will be working closely with OncoImmunity AS to customize the way we utilize Immuneoprofiler™ in order to optimize the use of the data we will be generating” said Reid Rubsamen, M.D. , CEO of Flow Pharma.
About OncoImmunity
OncoImmunity AS is a machine-learning company offering a proprietary technology to address key knowledge gaps in the prediction of bona fide immunogenic neoantigen for personalized cancer immunotherapy. OncoImmunity's software facilitates effective patient selection for cancer immunotherapy and identifies neoantigen targets creating truly personalized cancer vaccines & cell therapies in clinically actionable time-frames.
About Flow Pharma
Flow Pharma Inc. is a San Francisco Bay Area based, biotechnology company developing personalized neoantigen-based vaccines based on its proprietary FlowVax vaccine platform.
The FlowVax platform is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack. Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying the regulatory pathway. Flow Pharma is now gearing up to test therapeutic cancer vaccines based on the FlowVax platform.
About FlowVax TM
Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying the regulatory pathway. FlowVax vaccines can also be manufactured quickly and efficiently, keeping the cost down and getting the therapy in the hands of treating physicians soon after the diagnosis is made, for maximum efficacy.
However, as with all personalized vaccine approaches, the successful development and commercialisation of products based on the FlowVax platform is predicated on being able to identify clinically actionable and immunogenic neoantigen targets in a cost effective and clinically actionable time-frame. OncoImmunity’s Immuneoprofiler™ software, addresses this challenge, by harnessing the power of artificial intelligence (AI) to identify clinically relevant and immunogenic neoantigens from next generation sequencing data.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of Flow Pharma, Inc. (''the Company''), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words ''believes,''''expects,''''intends,''''plans,''''anticipates,'' or ''may,'' and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190312005768/en/
Contact:
Trevor Clancy Ph.D. CSO OncoImmunity E-mail: trevor@oncoimmunity.com Phone: + 47 41 43 12 42
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom